Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Eagle's Eye View: Your Weekly CV Update From ACC.org

Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension

28 May 2025

Description

In this week's View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol's effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension.    Subscribe to Eagle's Eye View  

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.